Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON29171
NL-OMON29171
Not yet recruiting
Not Applicable

The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with stiff knee gait.

Roessingh Research and DevelopmentRoessinghsbleekweg 337577 AH Enschede0 sites26 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIn the Netherlands live about 18.000 Cerebro Vascular Accident (CVA)-patients which discover problems with walking caused by insufficient footclearance. Causes of problems with the footclearance during the swing phase of gait are a combination of diminished dorsal flexion of the ankle, knee flexion and hip flexion. A diminished knee flexion during swing is defined a stiff knee gait. A stiff knee gait is often caused by an overactivity of the m. rectus femoris. Keywords: stroke, stiff knee gait

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
In the Netherlands live about 18.000 Cerebro Vascular Accident (CVA)-patients which discover problems with walking caused by insufficient footclearance. Causes of problems with the footclearance during the swing phase of gait are a combination of diminished dorsal flexion of the ankle, knee flexion and hip flexion. A diminished knee flexion during swing is defined a stiff knee gait. A stiff knee gait is often caused by an overactivity of the m. rectus femoris. Keywords: stroke, stiff knee gait
Sponsor
Roessingh Research and DevelopmentRoessinghsbleekweg 337577 AH Enschede
Enrollment
26
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Roessingh Research and DevelopmentRoessinghsbleekweg 337577 AH Enschede

Eligibility Criteria

Inclusion Criteria

  • •1\. Age over 18 years;
  • •2\. 6 months post stroke;

Exclusion Criteria

  • •1\. Presence of other constraints in joints who impede walking;
  • •2\. Neurological problems not causes by a Cerebro Vascular Accident;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Effect of botulinum toxin A injections and specific intensive rehabilitation therapy in children with hemiparetic cerebral palsy on upper limb functions and skills
ISRCTN69541857Ipsen Biopharm Ltd (UK)60
Active, not recruiting
Not Applicable
The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with a stiff knee gait. - Botulinum toxin type A injections in stiff knee gaitStroke patients with stiff knee gait. Stiff knee gait is characterized as a diminished knee flexion during swing phase of gait. It is common in stroke patients.
EUCTR2009-018226-29-NL26
Completed
Phase 3
The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with stiff knee gaitstiff knee gaitstiff-legged knee1000796310057166
NL-OMON39359Revalidatiecentrum Het Roessingh26
Completed
Phase 2
botulinum toxin type A and diabetic neuropathyDiabeticr polyneuropathy.Type 2 diabetes mellitus with diabetic polyneuropathyE10.42
IRCT20190129042540N1Rafsanjan University of Medical Sciences50
Active, not recruiting
Not Applicable
Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skills - BoBiVa (Botuline toxine Bimanuele Vaardigheden)Study design: a factorial design with four study groups in which btA alone, intensive rehabilitation therapy aimed at improving bimanual skills alone, a combination of these two and continuing the regular therapy program will be compared to each other.Study population: children with CP, spastic hemiparesis, aged 2.5 – 12 years.
EUCTR2006-002175-40-NL60